Nishimura T, Nagata S, Uehara T, Hayashida K, Mitani I, Kumita S
Department of Radiology, National Cardiovascular Center, Osaka, Japan.
J Nucl Med. 1991 Jul;32(7):1333-7.
For the detection of myocardial cell damage, an 111In-antimyosin Fab study was carried out on seven patients (Group A) in the dilated phase of hypertrophic cardiomyopathy, seven patients (Group B) with dilated cardiomyopathy, and eight control patients (Group C). Imaging was done 48 hr after intravenous injection of 74 MBq of 111In-antimyosin Fab. Myocardial antimyosin uptake was visually graded as 0, +1, +2 or +3. A score of +2 or +3 was considered positive. The heart/lung ratio of antimyosin uptake (antimyosin index) also was determined. Antimyosin uptake was positive in seven (100%), nine (90%) and no (0%) patients in Groups A, B, and C, respectively. The antimyosin index in Groups A and B was 2.46 +/- 0.49 and 2.04 +/- 0.24, respectively, findings were significantly higher than that in Group C (1.51 +/- 0.13) (p less than 0.01). Positive biopsy findings were noted in only two patients in Group A. Thus, antimyosin uptake was increased in dilated phase hypertrophic cardiomyopathy and dilated cardiomyopathy, which suggests ongoing necrotic changes in these patients.
为检测心肌细胞损伤，对7例肥厚型心肌病扩张期患者（A组）、7例扩张型心肌病患者（B组）和8例对照患者（C组）进行了铟-111抗肌凝蛋白Fab研究。静脉注射74MBq铟-111抗肌凝蛋白Fab后48小时进行成像。心肌抗肌凝蛋白摄取通过视觉分级为0、+1、+2或+3。+2或+3分被视为阳性。还测定了抗肌凝蛋白摄取的心脏/肺比值（抗肌凝蛋白指数）。A组、B组和C组抗肌凝蛋白摄取阳性的患者分别为7例（100%）、9例（90%）和0例（0%）。A组和B组的抗肌凝蛋白指数分别为2.46±0.49和2.04±0.24，结果显著高于C组（1.51±0.13）（p<0.01）。A组仅2例患者活检结果为阳性。因此，肥厚型心肌病扩张期和扩张型心肌病患者抗肌凝蛋白摄取增加，这表明这些患者存在进行性坏死改变。
